Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Raw Materials (2016 - 2025)

Historic Raw Materials for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $8.3 million.

  • Collegium Pharmaceutical's Raw Materials rose 9831.07% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year increase of 9831.07%. This contributed to the annual value of $12.5 million for FY2024, which is 2067.6% up from last year.
  • According to the latest figures from Q3 2025, Collegium Pharmaceutical's Raw Materials is $8.3 million, which was up 9831.07% from $9.5 million recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's Raw Materials ranged from a high of $14.4 million in Q3 2023 and a low of $3.7 million during Q4 2021
  • Its 5-year average for Raw Materials is $7.7 million, with a median of $7.2 million in 2024.
  • Its Raw Materials has fluctuated over the past 5 years, first surged by 14983.51% in 2023, then crashed by 7079.83% in 2024.
  • Quarter analysis of 5 years shows Collegium Pharmaceutical's Raw Materials stood at $3.7 million in 2021, then soared by 51.97% to $5.6 million in 2022, then surged by 85.43% to $10.4 million in 2023, then increased by 20.68% to $12.5 million in 2024, then tumbled by 33.48% to $8.3 million in 2025.
  • Its Raw Materials stands at $8.3 million for Q3 2025, versus $9.5 million for Q2 2025 and $11.8 million for Q1 2025.